Nivalis Therapeutics, Inc. 4
4 · Nivalis Therapeutics, Inc. · Filed Sep 14, 2016
Insider Transaction Report
Form 4
Furst Howard P.
Director
Transactions
- Award
Stock Option (Right to Buy)
2016-09-12+12,300→ 12,300 totalExercise: $7.77Exp: 2026-09-12→ Common Stock (12,300 underlying)
Footnotes (3)
- [F1]The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- [F2]The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.
- [F3]The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities.